Subsequent Event |
3 Months Ended |
|---|---|
Mar. 31, 2025 | |
| Subsequent Events [Abstract] | |
| Subsequent Event | 17. Subsequent Event On May 5, 2025, the Company entered into a license agreement (the “License Agreement”) with ABLi Therapeutics, Inc. (“ABLi”), pursuant to which the Company granted ABLi an exclusive license to develop, manufacture and commercialize certain abelson tyrosine kinase inhibitors, including risvodetinib (IkT-148009). If ABLi does not meet certain milestones with respect to the Licensed Material within 18 months, then the License Agreement will automatically terminate. Under the terms of the License Agreement, the Company received a nominal upfront payment and will be eligible to receive up to $47.5 million in development and regulatory milestone payments, along with tiered royalties based on net sales. |